Semaglutide, an anti-diabetic medication, did not slow Alzheimer’s disease progression in two large, placebo-controlled Phase…
Articles by Margarida Maia, PhD
Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second…
Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one…
Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main…
Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger…
September is awareness month for Alzheimer’s disease and other forms of dementia, and Alzheimer’s Disease International (ADI) is…
Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild…
Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, the first and largest to focus on people who have…
Nearly one year of treatment with blarcamesine (Anavex 2-73), a once-daily oral small molecule being developed by Anavex…
Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and…